{"id":"levodopa-benserazide","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Hallucinations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa crosses the blood-brain barrier and is converted to dopamine by aromatic amino acid decarboxylase (AADC), restoring dopaminergic neurotransmission in the basal ganglia. Benserazide is a peripheral decarboxylase inhibitor that does not cross the blood-brain barrier, preventing premature conversion of levodopa to dopamine in the periphery, thereby reducing systemic side effects and improving central nervous system bioavailability.","oneSentence":"Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter in Parkinson's disease, while benserazide inhibits peripheral conversion of levodopa to prevent side effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:01.693Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT07405268","phase":"","title":"Evaluation of the Effects of Levodopa-Benserazide Drug Combination on Periodontal Status in Patients With Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Saglik Bilimleri Universitesi","startDate":"2026-02-10","conditions":"Parkinson Disease (PD), Periodontitis, Periodontal Diseases","enrollment":136},{"nctId":"NCT06928519","phase":"","title":"Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study","status":"RECRUITING","sponsor":"Yousheng Xiao","startDate":"2025-06-05","conditions":"Parkinson Disease (PD)","enrollment":216},{"nctId":"NCT06729658","phase":"EARLY_PHASE1","title":"Dopamine and Brain Computer Interface","status":"COMPLETED","sponsor":"Max Planck Institute for Human Cognitive and Brain Sciences","startDate":"2017-10-01","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT06976346","phase":"PHASE1","title":"Relative Bioavailability Study of HRG2010 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-09-10","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT05204641","phase":"PHASE2","title":"Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2022-01-04","conditions":"Parkinson Disease","enrollment":59},{"nctId":"NCT04990284","phase":"PHASE4","title":"eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2021-11-29","conditions":"Parkinson Disease","enrollment":106},{"nctId":"NCT05711082","phase":"NA","title":"REALITY MONITORING","status":"RECRUITING","sponsor":"Hôpital le Vinatier","startDate":"2024-01-15","conditions":"Neurosciences","enrollment":39},{"nctId":"NCT06365515","phase":"NA","title":"Dopamine, Reward Learning and Sex Hormones","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2024-05","conditions":"Hormonal Changes, Menstrual Cycle","enrollment":90},{"nctId":"NCT02741947","phase":"PHASE4","title":"Levodopa Benserazide Generic Formulation Versus the Originator","status":"COMPLETED","sponsor":"IRCCS San Raffaele Roma","startDate":"2014-04","conditions":"Parkinson Disease","enrollment":44},{"nctId":"NCT06275633","phase":"NA","title":"Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD","status":"COMPLETED","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2019-03-19","conditions":"Parkinson Disease, Medication, UPDRS","enrollment":68},{"nctId":"NCT06115538","phase":"PHASE4","title":"Comparison of Dopamin Level in Idiopathic Parkinson's Patients","status":"UNKNOWN","sponsor":"Ankara Ataturk Sanatorium Training and Research Hospital","startDate":"2023-10-01","conditions":"Parkinson Disease, Treatment Adherence","enrollment":96},{"nctId":"NCT06034158","phase":"NA","title":"Molecular Basis of Loss Aversion","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2023-09-18","conditions":"Healthy","enrollment":60},{"nctId":"NCT04821687","phase":"PHASE4","title":"A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2021-06-17","conditions":"Parkinson Disease","enrollment":169},{"nctId":"NCT02601586","phase":"PHASE2, PHASE3","title":"Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2016-09","conditions":"Parkinson Disease","enrollment":67},{"nctId":"NCT04968613","phase":"PHASE4","title":"Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2018-01-01","conditions":"Parkinson Disease, Memory Impairment","enrollment":150},{"nctId":"NCT02769793","phase":"PHASE4","title":"Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2015-06","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT03541356","phase":"PHASE2","title":"Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal","status":"COMPLETED","sponsor":"Impel Pharmaceuticals","startDate":"2018-05-08","conditions":"Parkinson's Disease","enrollment":32},{"nctId":"NCT03891095","phase":"NA","title":"Oxytocin and Dopamine's Effect on Vicarious Optimism","status":"COMPLETED","sponsor":"Beijing Normal University","startDate":"2018-12-01","conditions":"Oxytocin Group, L-DOPA Group, Placebo Group","enrollment":156},{"nctId":"NCT01646255","phase":"PHASE3","title":"Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-07","conditions":"Idiopathic Parkinson's Disease","enrollment":346},{"nctId":"NCT03333369","phase":"EARLY_PHASE1","title":"Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2014-05-15","conditions":"Healthy, Schizotypal Personality","enrollment":65},{"nctId":"NCT03103399","phase":"PHASE2","title":"Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With \"Wearingoff\" Phenomenon","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-09-26","conditions":"Parkinson Disease","enrollment":254},{"nctId":"NCT03097211","phase":"PHASE1","title":"Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-07-17","conditions":"Parkinson Disease","enrollment":38},{"nctId":"NCT03094156","phase":"PHASE1","title":"Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-04-26","conditions":"Parkinson Disease","enrollment":39},{"nctId":"NCT03091543","phase":"PHASE1","title":"Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-05-04","conditions":"Parkinson Disease","enrollment":20},{"nctId":"NCT02073773","phase":"PHASE3","title":"Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2014-01","conditions":"Ischaemic Stroke","enrollment":9},{"nctId":"NCT02814201","phase":"","title":"Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2011-07","conditions":"Parkinson Disease, Huntington Disease","enrollment":55},{"nctId":"NCT02680977","phase":"PHASE2","title":"Mucuna Pruriens Therapy in Parkinson's Disease","status":"COMPLETED","sponsor":"ASST Gaetano Pini-CTO","startDate":"2016-02","conditions":"Parkinson's Disease","enrollment":18},{"nctId":"NCT02778594","phase":"PHASE1","title":"Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2005-09","conditions":"Parkinson's Disease (PD)","enrollment":17},{"nctId":"NCT02763852","phase":"PHASE1","title":"Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2001-04","conditions":"Parkinson's Disease","enrollment":18},{"nctId":"NCT01568047","phase":"PHASE2","title":"Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-02","conditions":"Parkinson's Disease","enrollment":40},{"nctId":"NCT02169414","phase":"PHASE1","title":"Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-02","conditions":"Parkinson's Disease (PD)","enrollment":74},{"nctId":"NCT01533116","phase":"PHASE1","title":"Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-03","conditions":"Parkinson Disease","enrollment":52},{"nctId":"NCT02169466","phase":"PHASE1","title":"Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-01","conditions":"Parkinson's Disease (PD)","enrollment":22},{"nctId":"NCT01227655","phase":"PHASE3","title":"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2011-03","conditions":"Parkinson's Disease","enrollment":427},{"nctId":"NCT01568073","phase":"PHASE3","title":"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With \"Wearing-off\" Phenomenon","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2011-03","conditions":"Parkinson's Disease","enrollment":600},{"nctId":"NCT02169895","phase":"PHASE1","title":"Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2008-09","conditions":"Parkinson's Disease (PD)","enrollment":16},{"nctId":"NCT01568034","phase":"PHASE2","title":"A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-04","conditions":"Parkinson's Disease","enrollment":10},{"nctId":"NCT00941265","phase":"NA","title":"Effect of Dopaminergic Medication on Recovery of Aphasia","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2007-02","conditions":"Aphasia","enrollment":12},{"nctId":"NCT00144209","phase":"PHASE3","title":"Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02","conditions":"Restless Legs Syndrome","enrollment":58},{"nctId":"NCT01327261","phase":"PHASE4","title":"Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Buenos Aires","startDate":"2009-08","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT00812760","phase":"PHASE4","title":"Effect of Levodopa on Human Multifocal Electroretinogram","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2001-10","conditions":"Retinal Diseases","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":190,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Levodopa + benserazide","genericName":"Levodopa + benserazide","companyName":"University of Buenos Aires","companyId":"university-of-buenos-aires","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while benserazide inhibits peripheral conversion of levodopa, allowing more to reach the central nervous system. Used for Parkinson's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}